Niharika B Mettu

6PUBLICATIONS
69CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Ezra Y Rosen, Timothy A Yap, Elisa Fontana

|Dec 16, 2024
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.

Van K Morris, Erin B Kennedy, Manik A Amin

|Aug 06, 2024
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Andrew L Coveler, Matthew J Reilley, Mark Zalupski

|Dec 20, 2023
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.

Pamela Munster, Nicholas Iannotti, Daniel C Cho

|Dec 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib.

Ezra Rosen, Timothy A Yap, Elizabeth K Lee

|Mar 22, 2019
A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.

Niharika B Mettu, Donna Niedzwiecki, Christel Rushing

Pageof 1